Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice

Anna Dabrowska, Adam Giermasz, Maria Marczak, Jakub Gołab, Marek Jakóbisiak

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The application of antiangiogenic agents in cancer therapy has been studied extensively. Combination of agents with antiangiogenic properties could possibly enhance antitumor effects. Interleukin 12 is a cytokine with potent antitumor activity mediated also via antiangiogenic mechanisms. These effects are attributed to IFN-γ production stimulated by IL-12. Since IFN-γ has been reported to augment antitumor effects when combined with one of the metalloproteinase inhibitors - batimastat (BB-94), we have examined a combined treatment with IL-12 and BB-94 in a murine melanoma model. The administration of both agents showed potentiated antitumor activity. Furthermore, we have shown in a tumor-induced angiogenesis model that the combined application of IL-12 and batimastat inhibits the formation of new blood vessels to a greater extent than either agent alone. Our observations show that antiangiogenic effects are at least partly responsible for the enhanced antitumor effects of the combined treatment with IL-12 and BB-94.

Original languageEnglish (US)
Pages (from-to)391-394
Number of pages4
JournalAnticancer Research
Volume20
Issue number1 A
StatePublished - 2000
Externally publishedYes

Fingerprint

Matrix Metalloproteinase Inhibitors
Interleukin-12
Melanoma
Angiogenesis Inhibitors
Metalloproteases
Blood Vessels
Neoplasms
batimastat
Cytokines

Keywords

  • Angiogenesis
  • Batismatat metalloproteinase inhibitor
  • Interleukin 12
  • Melanoma
  • Mice

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice. / Dabrowska, Anna; Giermasz, Adam; Marczak, Maria; Gołab, Jakub; Jakóbisiak, Marek.

In: Anticancer Research, Vol. 20, No. 1 A, 2000, p. 391-394.

Research output: Contribution to journalArticle

Dabrowska, Anna ; Giermasz, Adam ; Marczak, Maria ; Gołab, Jakub ; Jakóbisiak, Marek. / Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice. In: Anticancer Research. 2000 ; Vol. 20, No. 1 A. pp. 391-394.
@article{33c7f160e3474a2ba1d3a4dc1576c489,
title = "Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice",
abstract = "The application of antiangiogenic agents in cancer therapy has been studied extensively. Combination of agents with antiangiogenic properties could possibly enhance antitumor effects. Interleukin 12 is a cytokine with potent antitumor activity mediated also via antiangiogenic mechanisms. These effects are attributed to IFN-γ production stimulated by IL-12. Since IFN-γ has been reported to augment antitumor effects when combined with one of the metalloproteinase inhibitors - batimastat (BB-94), we have examined a combined treatment with IL-12 and BB-94 in a murine melanoma model. The administration of both agents showed potentiated antitumor activity. Furthermore, we have shown in a tumor-induced angiogenesis model that the combined application of IL-12 and batimastat inhibits the formation of new blood vessels to a greater extent than either agent alone. Our observations show that antiangiogenic effects are at least partly responsible for the enhanced antitumor effects of the combined treatment with IL-12 and BB-94.",
keywords = "Angiogenesis, Batismatat metalloproteinase inhibitor, Interleukin 12, Melanoma, Mice",
author = "Anna Dabrowska and Adam Giermasz and Maria Marczak and Jakub Gołab and Marek Jak{\'o}bisiak",
year = "2000",
language = "English (US)",
volume = "20",
pages = "391--394",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 A",

}

TY - JOUR

T1 - Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice

AU - Dabrowska, Anna

AU - Giermasz, Adam

AU - Marczak, Maria

AU - Gołab, Jakub

AU - Jakóbisiak, Marek

PY - 2000

Y1 - 2000

N2 - The application of antiangiogenic agents in cancer therapy has been studied extensively. Combination of agents with antiangiogenic properties could possibly enhance antitumor effects. Interleukin 12 is a cytokine with potent antitumor activity mediated also via antiangiogenic mechanisms. These effects are attributed to IFN-γ production stimulated by IL-12. Since IFN-γ has been reported to augment antitumor effects when combined with one of the metalloproteinase inhibitors - batimastat (BB-94), we have examined a combined treatment with IL-12 and BB-94 in a murine melanoma model. The administration of both agents showed potentiated antitumor activity. Furthermore, we have shown in a tumor-induced angiogenesis model that the combined application of IL-12 and batimastat inhibits the formation of new blood vessels to a greater extent than either agent alone. Our observations show that antiangiogenic effects are at least partly responsible for the enhanced antitumor effects of the combined treatment with IL-12 and BB-94.

AB - The application of antiangiogenic agents in cancer therapy has been studied extensively. Combination of agents with antiangiogenic properties could possibly enhance antitumor effects. Interleukin 12 is a cytokine with potent antitumor activity mediated also via antiangiogenic mechanisms. These effects are attributed to IFN-γ production stimulated by IL-12. Since IFN-γ has been reported to augment antitumor effects when combined with one of the metalloproteinase inhibitors - batimastat (BB-94), we have examined a combined treatment with IL-12 and BB-94 in a murine melanoma model. The administration of both agents showed potentiated antitumor activity. Furthermore, we have shown in a tumor-induced angiogenesis model that the combined application of IL-12 and batimastat inhibits the formation of new blood vessels to a greater extent than either agent alone. Our observations show that antiangiogenic effects are at least partly responsible for the enhanced antitumor effects of the combined treatment with IL-12 and BB-94.

KW - Angiogenesis

KW - Batismatat metalloproteinase inhibitor

KW - Interleukin 12

KW - Melanoma

KW - Mice

UR - http://www.scopus.com/inward/record.url?scp=0034070283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034070283&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 391

EP - 394

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 A

ER -